PRME · Prime Medicine, Inc. · Executive Compensation
$3.84
+0.02 (+0.52%)
At close · Nov 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 12, 2026
Market Cap
$698.58M
Shares
181.92M
Volume · Nov 19
3.99M
Avg daily vol (3M)
4.59M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Allan Reine | Chief Executive Officer | $3,894,187 |
| Keith Gottesdiener | Former Chief Executive Officer | $2,207,770 |
| Ann Lee | Chief Technical Officer | $1,550,116 |
| Jeremy Duffield | M.D., Ph.D., FRCP Former Chief Scientific Officer | $1,317,797 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Allan Reine | Chief Financial Officer | $4,623,802 |
| Keith Gottesdiener | President & Chief Executive Officer | $2,245,617 |
| Jeremy Duffield | M.D., Ph.D., FRCP Chief Scientific Officer | $1,877,577 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Keith Gottesdiener | President & Chief Executive Officer | $5,403,071 |
| Ann Lee | Chief Technical Officer | $2,264,362 |
| Jeremy Duffield | M.D., Ph.D., FRCP Chief Scientific Officer | $2,260,230 |
| Allan Reine | Chief Financial Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Richard Brudnick | Chief Business Officer | $1,443,954 |
| Ann Lee | Chief Technical Officer | $947,279 |
| Keith Gottesdiener | President & Chief Executive Officer | $924,044 |
| Jeremy Duffield | M.D., Ph.D., FRCP Chief Scientific Officer | $871,957 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ann Lee | Chief Technical Officer | $4,315,840 |
| Keith Gottesdiener | President & Chief Executive Officer | $2,939,433 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Svetlana Makhni | Chief Financial Officer and the principal financial officer | Appointed | 2026-04-16 |
| Jeffrey Marrazzo | Executive Chair of the Board | Appointed | 2025-05-19 |
| Allan Reine, M.D. | Chief Executive Officer and principal executive officer | Appointed | 2025-05-19 |
| Allan Reine, M.D. | Class II director | Appointed | 2025-05-19 |
|
Keith Gottesdiener, M.D.
“Dr. Gottesdiener’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
member of the Board of Directors | Resigned | 2025-05-19 |
|
Keith Gottesdiener, M.D.
“Dr. Gottesdiener’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.”
|
President, Chief Executive Officer and principal executive officer | Resigned | 2025-05-19 |
| Allan Reine | Chief Financial Officer and the principal financial officer | Appointed | 2024-01-05 |
| Jeff Marrazzo | director | Appointed | 2023-05-11 |
Leadership
- Allan Reine CEO, Board Member
- Allan Reine, M.D. CEO, Board Member
- Jeffrey Marrazzo Chairman
- Svetlana Makhni CFO
- Svetlana N. Makhni CFO
- Jeff Marrazzo Board Member
Key facts
CIK
1894562
CUSIP
74168J101
13F (30d)
194 filings
179 filers
Visit website
Investor relations